Anixa Biosciences (NASDAQ:ANIX) Posts Quarterly Earnings Results, Hits Expectations

Anixa Biosciences (NASDAQ:ANIX) posted its quarterly earnings data on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09), Zacks reports.

Anixa Biosciences Trading Down 6.5%

NASDAQ ANIX opened at $3.16 on Tuesday. The firm has a market cap of $104.03 million, a PE ratio of -9.03 and a beta of 0.49. Anixa Biosciences has a 1-year low of $2.07 and a 1-year high of $5.46. The stock has a 50-day moving average of $3.94 and a 200-day moving average of $3.60.

Institutional Trading of Anixa Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of ANIX. NewEdge Advisors LLC purchased a new stake in shares of Anixa Biosciences during the second quarter valued at approximately $33,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of Anixa Biosciences by 2,000.0% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after buying an additional 10,000 shares during the period. Benjamin Edwards Inc. purchased a new stake in Anixa Biosciences during the 2nd quarter valued at $37,000. Marshall Wace LLP bought a new stake in Anixa Biosciences in the 2nd quarter worth $39,000. Finally, CIBC Bancorp USA Inc. bought a new stake in Anixa Biosciences in the 3rd quarter worth $51,000. Institutional investors own 29.13% of the company’s stock.

Analyst Upgrades and Downgrades

ANIX has been the topic of a number of research reports. Wall Street Zen downgraded Anixa Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, December 27th. D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research report on Friday, December 12th. Zacks Research lowered Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Anixa Biosciences in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $9.00.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.